UniQure Shares Surge 6.14% on Gene Therapy Momentum, Rank 475th in Market Activity with $230M Volume

On October 9, 2025, uniQure (QURE) surged 6.14% with a trading volume of $230 million, ranking 475th in market activity. The biotech firm’s shares reacted to renewed investor interest in gene therapy advancements following recent clinical data releases. Analysts noted the move aligned with broader sector momentum as risk-on sentiment improved amid easing regulatory concerns.

Recent updates highlighted uniQure’s progress in its AMT-101 program for hemophilia B, with updated safety profiles from ongoing trials. While no new partnership announcements were disclosed, the company reaffirmed its 2026 development timeline, which has historically driven short-term volatility. Market participants also cited positioning adjustments ahead of Q3 earnings, which are expected to provide clarity on cash burn rates and manufacturing capacity expansion.

To run this back-test accurately I need to pin down a few practical details: Market universe • Do you want all U.S. exchange-listed common stocks, or a specific subset (e.g., S&P 500 constituents)? Weighting & sizing • Equal-weight each of the 500 names every day, or volume-proportional weighting? Trading price & costs • Enter at the close (or next day’s open) and exit at the next day’s close? • Any commission/slippage assumptions, or ignore costs? Data source constraints • Our back-test engine can process up to a few hundred tickers efficiently. If you truly need 500 names re-selected daily, I can still do it, but the run will take longer. Let me know if a smaller sample (e.g., top 100) is acceptable. Once I have these points I can pull the volume data, create the daily buy/sell signals, and feed them into the back-test engine.